- Home
- BQ vs ACXP Comparison
BQ vs ACXP Comparison
Compare BQ & ACXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BQ
- ACXP
- Stock Information
- Founded
- BQ 2008
- ACXP 2017
- Country
- BQ China
- ACXP United States
- Employees
- BQ N/A
- ACXP N/A
- Industry
- BQ Other Specialty Stores
- ACXP Biotechnology: Pharmaceutical Preparations
- Sector
- BQ Consumer Discretionary
- ACXP Health Care
- Exchange
- BQ Nasdaq
- ACXP Nasdaq
- Market Cap
- BQ 7.1M
- ACXP 6.8M
- IPO Year
- BQ 2020
- ACXP 2021
- Fundamental
- Price
- BQ $11.77
- ACXP $4.24
- Analyst Decision
- BQ
- ACXP Strong Buy
- Analyst Count
- BQ 0
- ACXP 3
- Target Price
- BQ N/A
- ACXP $143.67
- AVG Volume (30 Days)
- BQ 3.5M
- ACXP 89.0K
- Earning Date
- BQ 07-21-2025
- ACXP 11-12-2025
- Dividend Yield
- BQ N/A
- ACXP N/A
- EPS Growth
- BQ N/A
- ACXP N/A
- EPS
- BQ N/A
- ACXP N/A
- Revenue
- BQ $64,617,102.00
- ACXP N/A
- Revenue This Year
- BQ N/A
- ACXP N/A
- Revenue Next Year
- BQ N/A
- ACXP N/A
- P/E Ratio
- BQ N/A
- ACXP N/A
- Revenue Growth
- BQ N/A
- ACXP N/A
- 52 Week Low
- BQ $1.62
- ACXP $3.80
- 52 Week High
- BQ $46.70
- ACXP $43.20
- Technical
- Relative Strength Index (RSI)
- BQ 67.27
- ACXP 51.39
- Support Level
- BQ $8.75
- ACXP $3.97
- Resistance Level
- BQ $24.00
- ACXP $4.85
- Average True Range (ATR)
- BQ 5.77
- ACXP 0.35
- MACD
- BQ 1.02
- ACXP -0.02
- Stochastic Oscillator
- BQ 19.89
- ACXP 23.45
About BQ Boqii Holding Limited representing
Boqii Holding Ltd operates in the business of selling pet products through online stores. The store provides pet foods, health products, pet grooming products, pet bathing products, pet toys, fish tank, aquatic fertilizer, temperature control equipment, oxygen pump and other related products. Also, the company sells its products through offline channels to pet stores and hospitals.
About ACXP Acurx Pharmaceuticals Inc.
Acurx Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing a new class of antibiotics for infections caused by bacteria listed as priority pathogens by the World Health Organization, Centers for Disease Control and Prevention and Food and Drug Administration. The company's approach is to develop antibiotic candidates with a Gram-positive selective spectrum. The Company's segment consists of the development of clinical and preclinical product candidates for the development of the Company's proprietary new therapies.